Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
864 AVA-NP-695, a potent and selective ENPP1 inhibitor, demonstrates strong anti-tumor efficacy as monotherapy and in combination with radiation
Compose a Response to This Article
Other responses
No responses have been published for this article.
